The Tough Tech problem we are solving
Pathogenic antibodies drive autoimmune diseases like Graves' disease, allergies, and metabolic disorders by attacking the body's own tissues or harmless substances, yet existing treatments lack precision, efficacy, and durability, failing to address root causes and risking serious side effects.
About our solution
Merida Biosciences engineers highly-selective Fc biotherapeutics that bind pathogenic antibodies with precision, directing them to liver cells for lysosomal degradation while inhibiting the production of B cells for lasting elimination. This pioneering platform targets the root cause of inadequately treated autoimmune and allergic conditions, with a lead program rapidly clearing Graves' disease autoantibodies to deliver durable clinical responses.
